Mysoline (Primidone)

Primidone is converted in the liver to phenobarbital and phenylethylmalonamide, both of which enhance the activity of the inhibitory neurotransmitter GABA at neuronal receptors. This increased GABA‑mediated inhibition reduces neuronal excitability, helping to prevent seizure propagation and dampening tremor‑related pathways.

The appropriate dose of Mysoline is individualized by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and therapeutic response. Dosage adjustments are made during treatment to achieve optimal seizure control or tremor reduction while minimizing side effects.

Safety data for Primidone in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should only be used if the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in milk.

To request Mysoline, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Primidone is unique because it is metabolized to phenobarbital, offering a dual mechanism of action. Compared with newer agents, it may have a broader side‑effect profile but can be effective for patients who do not respond to first‑line drugs. Choice of therapy depends on individual patient factors and physician judgment.

Mysoline tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Maintaining a stable environment helps preserve potency and ensures the product remains safe for use throughout its shelf life.

Mysoline is taken orally, usually with a glass of water. The tablet can be swallowed whole and may be taken with or without food, as directed by the prescriber. Consistency in timing helps maintain stable blood levels of the medication.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, blood disorders like agranulocytosis, and significant liver injury. Patients should be monitored for signs of rash, unexplained bruising or bleeding, and jaundice, and should seek immediate medical attention if these occur.

Mysoline is contraindicated in patients with known hypersensitivity to Primidone, phenobarbital, or any of its excipients. Caution is also advised for individuals with severe hepatic or renal impairment, and it should be avoided in patients for whom abrupt discontinuation could precipitate withdrawal seizures.